Objective: Cancer and cardiovascular diseases both have adverse effects on each other. We aim in
the current study to investigate cardiac dysfunction including its prevalence, and associated
factors in patients treated for breast cancer and lymphoma in a unique cardiac oncology center.
Methods: A single-center retrospective study included 180 patients with cancer breast and lymphoma who presented and were treated at our oncology center from January 2019 to February
2022.
Result: Out of 180 consecutive patients, 155 patients (86 %) were diagnosed with cancer breast
and 25 patients (14 %) were diagnosed with lymphoma. Patients with lymphoma were older age,
less obese, and showed more prevalence of diabetes mellitus (DM) (P = 0.026, 0.05, and 0.04
respectively). They also showed more post-therapy left ventricular (LV) dilatation and lower
values of global longitudinal strain (GLS); however, they did not develop more LV dysfunction
compared to cancer breast patients. Moreover, lymphoma patients showed poor in-hospital
outcomes (P = 0.04, 0.001, and 0.015 for infection, pericardial effusion, and mortality respectively). Cancer therapy-related cardiac dysfunction (CTRCD) was observed in 41 patients (23 %)
of our population. The independent predictors of CTRCD in the current study were DM, low body
mass index (BMI), and the use of trastuzumab.
Conclusions: Some patients treated for breast cancer and lymphoma develop LV dysfunction.
Lymphoma patients showed more subclinical LV dysfunction and poor in-hospital outcomes
compared to patients with cancer breast. DM, low body mass index (BMI), and the use of trastuzumab were the independent predictors of cardiac dysfunction among our patients. |
